Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 9Phase 1/2 4Phase NA 2Phase 2/3 1Phase 1 1

Status

Completed 89Terminated 25Recruiting 18Active not recruiting 15Withdrawn 7Unknown 5Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 22fludarabine 17Specimen Handling 13Nivolumab 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Radiotherapy 6Cisplatin 6fludarabine phosphate 5Interleukin-2 5Injections 5Doxorubicin 5tislelizumab 4daratumumab 4Paclitaxel 4Ipilimumab 4Immune Checkpoint Inhibitors 4Drug Therapy 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3trastuzumab deruxtecan 3toripalimab 3ruxolitinib 3X-Rays 3Vincristine 3Rituximab 3Radiosurgery 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Pemetrexed × Clear all
NCT06594874 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
350 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡